Obviousness

Under 35 U.S.C. § 103, an invention is considered obvious if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA) to which the subject matter pertains. This analysis requires identifying the scope and content of the prior art, ascertaining the differences between the prior art and the claims at issue, and resolving the level of ordinary skill in the pertinent art. Crucially, there must be some teaching, suggestion, or motivation in the prior art that would have led a POSA to combine the references to achieve the claimed invention, with a reasonable expectation of success.

For US patent 12291566, the primary independent claims (Claims 1, 11, and 21) focus on an isolated mammalian anti-TNF antibody comprising a heavy chain (HC) with SEQ ID NO:36 and a light chain (LC) with SEQ ID NO:37, for use in treating active Ankylosing Spondylitis (AS) via intravenous (IV) infusion. Dependent claims further specify administration details and clinical endpoints.

Prior Art References

The patent itself provides key pieces of prior art:

1. Golimumab (Simponi) for active Ankylosing Spondylitis: The patent explicitly references a "trial of Simponi (golimumab), administered intravenously, in subjects with active Ankylosing Spondylitis (AS)" [cite: FIG. 18]. This reference directly teaches the treatment of active AS with an anti-TNF antibody via intravenous infusion, thereby covering the core indication and route of administration for an anti-TNF therapy.
2. cA2 (Infliximab) as an anti-TNF therapy: The patent discusses "beneficial effects in open-label trials with a chimeric monoclonal antibody to TNF alpha (cA2)" for rheumatoid arthritis and Crohn's disease [cite: beneficial effects in open-label trials with a chimeric monoclonal antibody to TNF alpha (cA2) have been reported with suppression of inflammation and with successful retreatment after relapse in rheumatoid arthritis and in Crohn's disease]. This establishes the broad utility of anti-TNF antibodies for inflammatory conditions.
3. General knowledge in antibody development and engineering: The patent extensively describes well-known methods for producing, isolating, humanizing, and engineering antibodies, including through hybridomas, recombinant techniques, transgenic animals, and display libraries [cite: Human antibodies that are specific for human TNF proteins or fragments thereof can be raised against an appropriate immunogenic antigen, such as isolated and/or TNF protein or a portion thereof (including synthetic molecules, such as synthetic peptides)., Monoclonal antibody production can be performed using any suitable technique., Suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or protein library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, or the like, display library..., single cell antibody producing technologies (e.g., selected lymphocyte antibody method (“SLAM”)..., a humanized or engineered antibody has one or more amino acid residues from a source which is non-human..., the anti-TNF antibody can also be optionally generated by immunization of a transgenic animal... capable of producing a repertoire of human antibodies)]. It also acknowledges that non-human or chimeric antibodies can elicit immune responses, providing motivation for developing human or humanized variants with improved safety profiles [cite: Such antibodies or fragments can elicit an immune response when administered to humans., repeated administration of antibodies or fragments comprising non-human portions can lead to serum sickness and/or anaphylaxis.].

Obviousness Analysis

A person having ordinary skill in the art (POSA) at the time of the invention (priority date: February 7, 2017) would have possessed a comprehensive understanding of immunology, molecular biology, and therapeutic antibody development. This would include knowledge of TNF-alpha as a validated therapeutic target for various inflammatory and autoimmune diseases.

Combination of References:

1. Golimumab (Simponi) for AS via IV infusion [cite: FIG. 18] and the general knowledge in antibody development [cite: Human antibodies that are specific for human TNF proteins or fragments thereof can be raised against an appropriate immunogenic antigen, such as isolated and/or TNF protein or a portion thereof (including synthetic molecules, such as synthetic peptides)., Monoclonal antibody production can be performed using any suitable technique., Suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or protein library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, or the like, display library..., single cell antibody producing technologies (e.g., selected lymphocyte antibody method (“SLAM”)..., a humanized or engineered antibody has one or more amino acid residues from a source which is non-human..., the anti-TNF antibody can also be optionally generated by immunization of a transgenic animal... capable of producing a repertoire of human antibodies)].

   • Motivation to Combine: A POSA would have been motivated to develop new anti-TNF antibodies for the treatment of active Ankylosing Spondylitis (AS) to improve upon existing therapies, such as golimumab, which was already known to be effective and administered intravenously for this condition [cite: FIG. 18 shows diagram of the study design for trial of Simponi (golimumab), administered intravenously, in subjects with active Ankylosing Spondylitis (AS)]. The continuous drive in pharmaceutical research is to identify therapeutic agents with enhanced efficacy, better safety profiles (e.g., reduced immunogenicity compared to chimeric antibodies like infliximab), more convenient dosing regimens, or improved pharmacokinetic properties. The patent itself highlights the potential for immune responses to non-human antibody portions, providing a clear motivation to seek fully human or humanized antibodies [cite: Such antibodies or fragments can elicit an immune response when administered to humans., repeated administration of antibodies or fragments comprising non-human portions can lead to serum sickness and/or anaphylaxis.].
   • Reasonable Expectation of Success: Given the established role of TNF-alpha in AS, and the success of existing anti-TNF therapies, a POSA would have a reasonable expectation of success in developing new anti-TNF antibodies that bind to TNF-alpha and are efficacious in AS. The numerous known methods for discovering, engineering, and optimizing antibodies, including screening diverse antibody libraries or immunizing transgenic animals to produce human antibodies, would provide a POSA with the tools to achieve this [cite: Human antibodies that are specific for human TNF proteins or fragments thereof can be raised against an appropriate immunogenic antigen, such as isolated and/or TNF protein or a portion thereof (including synthetic molecules, such as synthetic peptides)., Monoclonal antibody production can be performed using any suitable technique., Suitable methods of producing or isolating antibodies of the requisite specificity can be used, including, but not limited to, methods that select recombinant antibody from a peptide or protein library (e.g., but not limited to, a bacteriophage, ribosome, oligonucleotide, RNA, cDNA, or the like, display library..., single cell antibody producing technologies (e.g., selected lymphocyte antibody method (“SLAM”)..., a humanized or engineered antibody has one or more amino acid residues from a source which is non-human..., the anti-TNF antibody can also be optionally generated by immunization of a transgenic animal... capable of producing a repertoire of human antibodies)]. The administration route (IV infusion) and the clinical efficacy endpoints (e.g., ASDAS inactive disease, ASAS20) are standard in the field of AS treatment and would be routinely applied in the evaluation of any new anti-TNF therapy.

While the specific amino acid sequences (SEQ ID NO:36 and SEQ ID NO:37) of the claimed antibody are not explicitly disclosed in the cited prior art, the general concept of identifying and optimizing novel anti-TNF antibodies to treat AS via IV infusion, with the goal of improving existing treatments, would be considered an obvious endeavor for a POSA using well-established techniques. The patent's own description of standard antibody discovery methods supports the view that such a search for new antibodies against a known target like TNF-alpha was routine. Any unexpected superior efficacy of the claimed antibody (as suggested in the patent's examples comparing TNV148 to cA2 in mouse models) would be a factor in rebutting a prima facie case of obviousness.